EQT Life Sciences

ONWARD Medical is advancing the treatment of spinal cord injuries with innovative technologies, including the first-ever device with the potential to restore hand strength and sensation. For many SCI patients, regaining even partial function in these areas profoundly impacts their independence. • 𝗜𝗻 𝗮 𝗿𝗲𝗰𝗲𝗻𝘁 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘀𝘁𝘂𝗱𝘆, 𝟵𝟬% 𝗼𝗳 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁𝘀 𝗿𝗲𝗴𝗮𝗶𝗻𝗲𝗱 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵 𝗼𝗿 𝗳𝘂𝗻𝗰𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗔𝗥𝗖- 𝗘𝗫 𝘀𝘆𝘀𝘁𝗲𝗺. • 𝗘𝘃𝗲𝗻 𝗮 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗶𝗻𝗷𝘂𝗿𝗲𝗱 𝟯𝟬+ 𝘆𝗲𝗮𝗿𝘀 𝗮𝗴𝗼 𝘀𝗮𝘄 𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗿𝗲𝘀𝘂𝗹𝘁𝘀. • 𝟴𝟳% 𝗿𝗲𝗽𝗼𝗿𝘁𝗲𝗱 𝗮𝗻 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗼𝗳 𝗹𝗶𝗳𝗲. When it received FDA approval in December, ARC-EX became the first technology shown to improve hand strength and sensation in paralyzed people. Tara stewart chair of Spinal Research, called it a “historic moment” which the charity had “been working towards for 40 years”. EQT Life Sciences, formerly called LSP and now a part of EQT Group, has invested in Onward at multiple stages of its journey. EQT’s role as an investor had been to guide the company’s strategic growth and help it launch products. “𝗧𝘆𝗽𝗶𝗰𝗮𝗹𝗹𝘆, 𝗯𝗿𝗶𝗻𝗴𝗶𝗻𝗴 𝗮 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝘁𝗼 𝗺𝗮𝗿𝗸𝗲𝘁 𝗰𝗮𝗻 𝘁𝗮𝗸𝗲 𝗮𝗻𝘆𝘄𝗵𝗲𝗿𝗲 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝟭𝟬 𝗮𝗻𝗱 𝟮𝟬 𝘆𝗲𝗮𝗿𝘀,” says John de Koning, a partner in the EQT Life Sciences team. “It's very, very difficult to make something new in the healthcare sector, especially if it relates to drugs or medical devices https://lnkd.in/e79GSN7m

EQT Life Sciences leads USD 97 million Series B in Atalanta Therapeutics, a biotech firm developing treatments for epilepsy and Huntington’s disease Learn more about the investment here: https://lnkd.in/eezRaXcU

At EQT Life Sciences we are "reflecting on a Transformative 2024: Advancing Innovation in Life Sciences" Wishing you a great 2025!

We are looking forward to this year’s edition of BioCapital Europe (5 & 6 Feb). Registration will close soon so be sure to secure your spot! https://lnkd.in/eAZaaqrC

EQT Life Sciences Leads Series B Extension in Noema Pharma, Raising Total Series B Financing to CHF130 Million. Noema Pharma is a clinical-stage biotech company developing a pipeline of first-in-disease therapeutics that address central nervous system (CNS) disorders. The investment builds on EQT Life Sciences’ previous successful partnership with neurology-focused repeat entrepreneur and Noema Pharma CEO Ilise Lombardo , MD. Learn more about the investment here: https://lnkd.in/dH6qnE9s

C-sections are the most common major surgical procedure globally, with over 30 million performed each year. Innovation within this area of maternal health has the potential to improve the quality of care and reduce healthcare costs for millions. Against this backdrop, EQT Life Sciences has lead NUA SURGICAL's Series A funding round. Nua Surgical's surgical retractor, which is specifically designed for the unique dynamics of C-section surgery, aims to reduce the risk factors that lead to surgical complications, benefiting the patient, the clinician, and the healthcare system. Learn more about the investment here: https://lnkd.in/emCZ5G-3

Exciting news from our EQT Life Sciences portfolio company Tubulis GmbH, congratulations on this great achievement.

Congrats to the Tubulis GmbH Team for winning two awards in one night! Well deserved. It is also the second time in a row an EQT Life Sciences Life Sciences portfolio company is named Biotech Company of the Year after Amolyt Pharma Pharma took the price home last year. A testament to these outstanding companies, their teams, and top notch science.

EQT Life Sciences is pleased to announce that its LSP 7 fund has invested in atbtherapeutics. The €54 Million Series A financing was co-led by EQT Life Sciences and MRL Ventures Fund (MRLV, a corporate venture arm of Merck & Co., Inc., Rahway, N.J., USA) alongside contributions from V-Bio Ventures, VIVES Partners, the Belgian sovereign fund SFPIM-International, Wallonie Entreprendre, Sambrinvest, and existing investors. ATB Therapeutics is dedicated to pioneering first-in-class biologics that incorporate novel cell-killing mechanisms, including enzymatic functionalities, within targeted antibodies. The Company is also welcoming seasoned biotech investors John de Koning, Partner at EQT Group, and Karin Kleinhans, Partner at MRLV, to its Board of Directors https://lnkd.in/ehetdfvG

Exciting news from the EQT Life Sciences Dementia Fund, where AviadoBio, one of our portfolio companies, just entered into an Option and License Agreement with Astellas Pharma. Under this agreement, AviadoBio granted Astellas Pharma an exclusive option to license their progranulin gene therapy program upon the readout of an ongoing phase 1/2 clinical study in frontotemporal dementia. By exercising their option to license , Astellas Pharma will trigger payment of a substantial license fee and potential development and commercialisation milestone payments to AviadoBio. As part of this deal, Astellas Pharma also made an equity investment in the Series B round of AviadoBio, which closed simultaneously today. https://lnkd.in/eaJbhb4c